New fluoroquinolones: Levofloxacin, moxifloxacin and gatifloxacin;Nieuwe fluorochinolonen: Levofloxacine, moxifloxacine en gatifloxacine

Nederlands Tijdschrift voor Geneeskunde

Volumn 148, Issue 43, 2004, Pages 2115-2121

  Hoepelman, I M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIBIOTIC AGENT; CIPROFLOXACIN; COUMARIN DERIVATIVE; DIGOXIN; GATIFLOXACIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LEVOFLOXACIN; MOXIFLOXACIN; NEW DRUG; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THEOPHYLLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CARDIOTOXICITY; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG HALF LIFE; DRUG INDICATION; GASTROINTESTINAL TOXICITY; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HUMAN; HYPOGLYCEMIA; MINIMUM INHIBITORY CONCENTRATION; NEUROTOXICITY; NONHUMAN; PHARMACODYNAMICS; PSYCHOSIS; RESPIRATORY TRACT INFECTION; RHINOSINUSITIS; TORSADE DES POINTES;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; OFLOXACIN; PNEUMONIA; QUINOLINES; RESPIRATORY TRACT INFECTIONS;

EID: 7444221340     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Ketel RJ van. Chinolonen. Ned Tijdschr Geneeskd 1987;131:1467-9.
2. Scheid WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003;9:1-9.
3. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001;7:589-96.
4. Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Hallow CH, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998;2:521-7.
5. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004;189:1590-7.
6. Shea KM. Antibiotic resistance: what is the impact of agricultural uses of antibiotics on children's health? Pediatrics 2003;112(1 Pt 2):253-8.
7. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999;341:233-9.
8. Perez-Trallero E, Garcia-Rey C, Martin-Sanchez AM, Aguilar L, Garcia-de-Lomas J, Ruiz J. Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain. Spanish Surveillance Group for Respiratory Pathogens (SAUCE Program). Antimicrob Agents Chemother 2002;46:2665-7.
9. Pestova E, Millichap JJ, Noskin GA, Peterson LR. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J Antimicrob Chemother 2000;45:583-90.
10. Owens jr RC, Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy 2002;22:663-8.
11. Baker SE, Hangii MC. Possible gatifloxacin-induced hypoglycemia. Ann Pharmacother 2002;36:1722-6.
12. Williams jr JW, Aguilar C, Cornell J, Chiquette ED, Makela M, Holleman DR, et al. Antibiotics for acute maxillary sinusitis [Cochrane review]. The Cochrane Library. Issue 2. Oxford: Update Software; 2003.
13. Varonen H, Kunnamo I, Savolainen S, Makela M, Revonta M, Ruotsalainen J, et al. Treatment of acute rhinosinusitis diagnosed by clinical criteria or ultrasound in primary care. A placebo-controlled randomised trial. Scand J Prim Health Care 2003;21:121-6.
14. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
15. Kasteren MEE van, Wijnands WJA, Stobberingh EE, Janknegt R, Meer JWM van der. Optimaliseren van het antibioticabeleid in Nederland. III. SWAB-richtlijnen voor antimicrobiële therapie bij volwassenen met bronchitis in het ziekenhuis. Ned Tijdschr Geneeskd 1998;142:2512-5.
16. Chodosh S, Schreurs A, Siami G, Barkman jr HW, Anzueto A, Shan M, et al. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis 1998;27:730-8.
17. Fogarty C, Dowell MC, Ellison WT, et al. Treating community-acquired pneumonia in hospitalized patients: gatifloxacin vs ceftriaxone/clarithromycin. J Respir Dis 1999;20(II Suppl):S60-9. Geciteerd in: Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000;31:383-421.
18. Fogarty C, Dowell MC, Ellison WT, et al. Treating community-acquired pneumonia in hospitalized patients: gatifloxacin vs ceftriaxone/clarithromycin. J Respir Dis 1999;20(II Suppl):S60-9. Geciteerd in: Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000;31:383-421.
19. Ramirez JA, Nguyen T, Tellier G, et al. Treating community-acquired pneumonia with once-daily gatifloxacin vs twice-daily clarithromycin. J Respir Dis 1999;20(II Suppl):S40-8. Geciteerd in: Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000;31:383-421.
20. Ramirez JA, Nguyen T, Tellier G, et al. Treating community-acquired pneumonia with once-daily gatifloxacin vs twice-daily clarithromycin. J Respir Dis 1999;20(II Suppl):S40-8. Geciteerd in: Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000;31:383-421.
21. Sullivan JG, McElroy A, Hansinger RW, et al. Treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin. J Respir Dis 1999;20(II Suppl):S49-59. Geciteerd in: Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000;31:383-421.
22. Sullivan JG, McElroy A, Hansinger RW, et al. Treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin. J Respir Dis 1999;20(II Suppl):S49-59. Geciteerd in: Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000;31:383-421.
23. File jr TM, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-72.
24. Fogarty C, Ramirez L, de Abate L, et al. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect Med 1999;16:748-63. Geciteerd in: Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000;31:383-421.
25. Fogarty C, Ramirez L, de Abate L, et al. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect Med 1999;16:748-63. Geciteerd in: Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000;31:383-421.
26. Finch R, Schürmann D, Collins O, Kubin R, McGivern J, Bobbaers H, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral coamoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002;46:1746-54.
27. Gotfried MH, Dattani D, Riffer E, Devcich KJ, Busman TA, Notario GF, et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Ther 2002;24:736-51.
28. Frank E, Liu J, Kinasewitz G, Moran GJ, Gross MP, Olson WH, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002;24:1292-308.
29. Norrby SR, Petermann W, Willcox PA, Vetter N, Salewski E. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998;30:397-404.
30. Petitpretz P, Arvis P, Marel M, Moita J, Urueta J. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. CAP5 Moxifloxacin Study Group. Chest 2001;119:185-95.
31. Correa JC, Badaro R, Bumroongkit C, Mera JR, Dolmann AL, Juarez Martinez LG, et al. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization. Clin Ther 2003;25:1453-68.
32. Torres A, Muir JF, Corris P, Kubin R, Duprat-Lomon I, Sagnier PP, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J 2003;21:135-43.
33. Frank E, Liu J, Kinasewitz G, Moran GJ, Oross MP, Olson WH, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002;24:1292-308.
34. Salkind AR, Cuddy PG, Foxworth JW. Fluoroquinolone treatment of community-acquired pneumonia: a meta-analysis. Ann Pharmacother 2002;36:1938-43.
35. Hoepelman IM. Legionella-epidemie in Nederland. Ned Tijdschr Geneeskd 1999;143:1192-6.
36. Yu VL, Greenberg RN, Zadeikis N, Stout JE, Khashab MM, Olson WH, et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest 2004;125:2135-9.
37. Bohte R, Furth R van, Broek PJ van den. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax 1995;50:543-7.
38. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. New Engl J Med 1997;336:243-50.
39. Lettinga KD, Verbon A, Weverling GJ, Schellekens JF, Boer JW den, Yzerman EP, et al. Legionnaires' disease at a Dutch flower show: prognostic factors and impact of therapy. Emerg Infect Dis 2002;8:1448-54.
40. Lode H, Grossman C, Choudhri S, Haverstock D, McGivern J, Herman-Gnjidic Z, et al. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. Respir Med 2003;97:1134-42.